Accepted_test

The disacсharide trehalose has the ability to treat neurodegeneration, including models of Alzheimer's disease (AD) [Khalifeh et al., 2021]. The predominant mode of treatment is the addition of trehalose to drinking (2% solution) [ He et al., 2016]. Nevertheless, it is of interest to find optimal administration regimens for trehalose, and to study the efficacy of trehalose treatment depending on the age of mice [ Yap et al, 2022]. Here, the dose-dependent therapeutic effect of trehalose (2%, 4% and 4% in intermittent regimen) was studied in a pharmacologic model of AD [Tikhonova et al, 2020].  All variants of two-week trehalose treatment induced autophagy (especially 4% trehalose), dramatically reduced the levels of the disease markers Aβ and Iba1 and improved cognitive abilities in the passive avoidance test, with the maximum effect of 4% trehalose in the continuous mode.

Next, we examined the age-dependent efficacy of trehalose treatment of 5xFAD mice with a transgenic model of AD. At 2 months of age, the mice are characterized by Aβ accumulation in the brain, and at 6 months of age they demonstrate phenotypic cognitive impairment [Webster et al., 2014]. The main results of the therapy efficacy were obtained in the passive avoidance test, which were sharply reduced in transgenic mice. Trehalose treatment was effective for all groups of mice of different ages with greater significance for the mature 5-month-old, which is relevant for a possible translational transition.